|1.||Scholl, Dean: 3 articles (12/2011 - 05/2008)|
|2.||Williams, Steven R: 2 articles (12/2011 - 06/2008)|
|3.||Gebhart, Dana: 2 articles (12/2011 - 06/2008)|
|4.||Martin, David W: 2 articles (06/2008 - 05/2008)|
|5.||Griffin, Ashleigh S: 1 article (09/2015)|
|6.||Molin, Søren: 1 article (09/2015)|
|7.||Jelsbak, Lars: 1 article (09/2015)|
|8.||Bruce, John B: 1 article (09/2015)|
|9.||Johansen, Helle Krogh: 1 article (09/2015)|
|10.||Ghoul, Melanie: 1 article (09/2015)|
12/01/2011 - "An Escherichia coli O157-specific engineered pyocin prevents and ameliorates infection by E. "
09/07/2015 - "Our results show that, in contrast to patterns observed in experimental studies, pyocin production does not appear to have a major influence on strain competition during CF lung infections."
01/01/1991 - "[Serotyping and pyocin typing of Pseudomonas aeruginosa in a study of intrahospital infections]."
03/01/2012 - "aeruginosa infection, we also show that pyocin S2 is highly active in vivo."
12/01/2011 - "Our findings support the further development of pathogen-specific R-type pyocins as a way to treat enteric infections."
|4.||Cross Infection (Nosocomial Infection)
07/01/1991 - "More studies are needed to compare results of pyocin typing with methods such as genome fingerprinting to characterize these strains and determine whether the observed distribution of pyocin groups in CF isolates is related to cross-infection or whether the combination of pyocin type 9 with polyagglutinating serotype is a characteristic of CF strains."
09/01/1971 - "Subtyping of pyocin type 1 Pseudomonas aeruginosa strains has increased the sensitivity of an epidemiological tool used by the Hospital Infection Committee in surveillance studies."
10/01/1987 - "The reliability of this technique for detecting nosocomial cross infections was assessed by comparing its results with that of serotyping and pyocin typing. "
05/01/1986 - "aeruginosa strains, identical in their serovar and pyocin type, is indicative of the presence of hospital infection and, therefore, the endogenous character of the contamination of patients. "
09/25/1982 - "Over a 12-months period respiratory Pseudomonas aeruginosa isolated from CF patients were typed by serology and pyocin production to determine whether cross-infection was occurring. "
|5.||Cystic Fibrosis (Mucoviscidosis)
04/14/1995 - "The genetic determinant for the soluble pyocin S3 was isolated from a genomic library constructed in the plasmid pGV1122, of Pseudomonas aeruginosa strain P12 isolated from a cystic fibrosis patient. "
07/01/1991 - "Pyocin typing and serotyping of 433 strains of Pseudomonas aeruginosa from children with cystic fibrosis (CF) showed that pyocin type 9 was predominant, particularly in association with polyagglutinating serotype. "
07/01/1991 - "Pyocin typing of Pseudomonas aeruginosa isolates from children with cystic fibrosis."
07/01/1990 - "Incidence of common pyocin types of Pseudomonas aeruginosa from patients with cystic fibrosis and chronic airways diseases."
05/01/1990 - "178 polyagglutinable Pseudomonas aeruginosa isolates from cystic fibrosis patients were serotyped using polyclonal sera and monoclonal antibodies, phage typed, pyocin typed and reverse phage typed. "
|2.||Blood Group Antigens (Blood Groups)
|5.||Immune Sera (Antisera)
|7.||Anti-Bacterial Agents (Antibiotics)